Co-Development Guidance Gives More Attention To IND, NDA/BLA Submissions
This article was originally published in The Pink Sheet Daily
In a final guidance on co-development of two or more investigational new drugs for use in combination, FDA lays out general principles for IND and marketing application submissions, a topic on which the agency essentially punted in a December 2010 draft document.
You may also be interested in...
ASCO's chief medical officer Richard Schilsky discusses innovative clinical trial designs in oncology, challenges facing developers of cancer combination therapies and future developments for the society's value frameworks.
Master protocols that allow for the simultaneous study of multiple agents will shave more time off in the clinic than one-off studies in small groups of patients, FDA’s Janet Woodcock predicted. The current timeframes in oncology development are “unacceptable,” and can be shortened, she said, by “doing things differently.”
Beyond saving money and creating efficiencies, stakeholders want a master trial to foster true innovation in metastatic breast cancer treatment. Various ways to deal with dosing and other challenges in testing rational combinations of different interventions were discussed at recent workshop.